SPHK2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL312540	0.69	14/20
Sphingosine (SCHEMBL19398)	1.00	12/20
Sphingosine (SCHEMBL19399)	1.00	12/20
Sphingosine (SCHEMBL195874)	0.97	12/20
Sphingosine (SCHEMBL195875)	0.97	12/20
SCHEMBL19994	0.50	12/20
SCHEMBL95836	0.57	11/20
SCHEMBL94738	0.57	11/20
SCHEMBL95835	0.54	11/20
SCHEMBL94737	0.54	11/20
SCHEMBL94884	0.56	10/20
SCHEMBL96694	0.56	8/20
SCHEMBL206151	0.51	8/20
SCHEMBL205369	0.59	7/20
SCHEMBL96693	0.53	7/20
SCHEMBL3691	0.41	7/20
SCHEMBL258143	0.40	7/20
SCHEMBL223135	0.40	7/20
SCHEMBL223136	0.40	7/20
SCHEMBL29418	0.38	7/20

Clinical trials — most relevant to SPHK2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study	PHASE4	COMPLETED
A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple Sclerosis	PHASE4	WITHDRAWN
Sphingosine-1-phosphate and Pneumonia	PHASE2/PHASE3	UNKNOWN
Repurposing Siponimod for Alzheimer's Disease	PHASE2	RECRUITING
Fingolimod in Schizophrenia Patients	PHASE2	COMPLETED
Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma	PHASE1/PHASE2	WITHDRAWN
Vascular Protective Effect of Rosuvastatin in Arteriovenous Fistula	PHASE2	COMPLETED
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors	PHASE2	RECRUITING
A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers.	PHASE1	COMPLETED
A Clinical Trial to Assess the Safety of SOR102 in Healthy Participants and Patients With Ulcerative Colitis	PHASE1	COMPLETED
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia	nan	UNKNOWN
Vulvodynia: Identification of Potential Relevant Biomarkers	nan	COMPLETED
Identification of Biomarkers and Molecular Targets Involved on Intervertebral Disc Degeneration and Discogenic Pain	nan	UNKNOWN
Evaluating the Association Between Sphingolipid Metabolites and Post-hepatectomy Liver Failure	nan	COMPLETED
Longitudinal Assessment of Marrow and Blood in Patients With Glioblastoma	nan	SUSPENDED
Disease Control in RRMS Transferring Treatment From Natalizumab to Fingolimod	nan	COMPLETED
Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study	nan	UNKNOWN
Plasma Sphingolipid Metabolites and Radiotherapy Efficacy in Hepatocellular Carcinoma	nan	RECRUITING
Plasma Dihydroceramides Are Associated With Hepatic Steatosis in Type 1 and Type 2 Diabetes	nan	COMPLETED
Duality of Lipids: the Athlete's Paradox	nan	COMPLETED
Development of Therapeutic Approaches Modulating Molecular Targets Implicated on Cancer Stem Cell-related Aggressiveness	nan	UNKNOWN
Skeletal Muscle Diacylglycerol and Sphingolipids - Impact of Localization and Species on Insulin Resistance in Humans	nan	COMPLETED
The ASTERS Study: Assessing the Role of Sphingolipids in AcuTE Respiratory Distress Syndrome (ARDS)	nan	COMPLETED
Effect of Plasma Ceramides on Peripheral Vascular Function	nan	COMPLETED
Free Fatty Acid Induced Insulin Resistance	nan	COMPLETED
Ceramide Level as Apredictor of Outcomes in Patients of Anterior Myocardial Infarction Undergoing Primary Coronary Intervention	nan	UNKNOWN
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED
Serum Sphingolipidomic Analyses in Healthy, Diabetic and Prediabetic Subjects	nan	UNKNOWN
The Heart-Mind Connection: Evaluating the Association Between Ceramides and Cognitive Decline in Coronary Artery Disease	nan	COMPLETED
The Role of Arachidonic Acid Metabolites, From Patients With Metabolic Syndrome	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a SPHK2 binder may also engage these)

Protein	Name	Similarity
Q9JIA7	—	1.000	Q9JIA7 →
Q7Z736	—	0.971	Q7Z736 →
Q8VCE9	—	0.970	Q8VCE9 →
Q8N398	—	0.970	Q8N398 →
Q3B7L1	—	0.968	Q3B7L1 →
Q5EBP3	—	0.968	Q5EBP3 →
SHARPIN	Sharpin (Shank-associated RH domain-interacti	0.967	landscape →
Q7L591	—	0.966	Q7L591 →
Q8N1F8	—	0.966	Q8N1F8 →
B2RYG7	—	0.966	B2RYG7 →
Q96C12	—	0.965	Q96C12 →
Q5PQP9	—	0.965	Q5PQP9 →
Q8TDF6	—	0.964	Q8TDF6 →
Q8NAG6	—	0.963	Q8NAG6 →
PKN1	Serine/threonine-protein kinase N1	0.963	landscape →
Q9QZK7	—	0.963	Q9QZK7 →
A4D2P6	—	0.963	A4D2P6 →
Q9BG99	—	0.963	Q9BG99 →
Q8N2A8	—	0.962	Q8N2A8 →
M0RDU0	—	0.962	M0RDU0 →
P23610	—	0.962	P23610 →
PKN3	Serine/threonine-protein kinase N3	0.962	landscape →
Q69Z89	—	0.961	Q69Z89 →
Q91ZT7	—	0.961	Q91ZT7 →
A1L515	—	0.961	A1L515 →
Q0IIA6	—	0.961	Q0IIA6 →
Q5U4P2	—	0.961	Q5U4P2 →
Q3UR50	—	0.961	Q3UR50 →
Q86UR1	—	0.961	Q86UR1 →
Q9H3T2	—	0.961	Q9H3T2 →